Coriolis Pharma, a globally operating service provider for R&D and GMP drug product development, R&D and GMP analytics and sterile drug product manufacturing support, has launched a U.S. entity.
 
U.S. customers will be served by the U.S.-based Coriolis commercial organization, which consists of business development and client project management professionals.
 
Coriolis is also launching two novel platform services for developability assessment and pre-formulation screening, designed to de-risk and accelerate the path of antibody drug candidates to the clinic. The new platform services are streamlined encapsulations of   Coriolis’ scientific experience with over 1,500 successful biologics development projects in all stages of development, including commercial products.
 
The new U.S. entity and platform services aims to offer clients more convenience and faster access to the company’s scientific expertise.

About the New Platform Services

Coriolis’ science-based developability assessment platform for antibodies enables the selection of candidates with optimal biophysical properties for successful drug product development, scale-up, and market launch. This service package is highly beneficial for projects with low material availability (in the single-digit mg space) per antibody candidate. Projects can start immediately with innovative pricing models that appeal to small biotech start-ups and Big Pharma companies alike.
 
Meanwhile, Coriolis’ new systemic antibody pre-formulation platform generates a comprehensive data set for holistic drug product development by systemically screening a vast antibody-relevant formulation space of excipients from FDA-approved drugs. Readouts from predictive methods, as well as assessment of critical Quality Attributes (cQA) through accelerated stress testing, facilitate the selection of the best lead formulations for subsequent stability studies and further pre-clinical development. The service package mitigates risk by ensuring that an antibody can be developed into a commercial product in line with the clients’ Quality Target Product Profile (QTPP) with a stable formulation right from the start.